Mckesson Corpation and its Affiliate US Oncology (Formerly US Oncology)
Based in TX
🤖
AI Overview
With $1.6M in lobbying spend across 27 quarterly filings, Mckesson Corpation and its Affiliate US Oncology (Formerly US Oncology) is a significant lobbying presence.
$1.6M
Total Lobbying Spend
27
Quarterly Filings
1
Lobbying Firms Used
9
Individual Lobbyists
Spending by Year
| Year | Lobbying Spend |
|---|---|
| 2018 | $240K |
| 2019 | $120K |
| 2020 | $180K |
| 2021 | $240K |
| 2022 | $180K |
| 2023 | $240K |
| 2024 | $180K |
| 2025 | $240K |
Lobbying Firms
STANTON PARK GROUP
What They Lobby For
- Medicare, oncology, radiation and imaging reimbursement issues Medicare physician payments prompt pay discount Oncology payment disparities in Medicare and protecting access to community based cancer care Reimbursement of cancer care services by the Veterans Administration Issues related to physician reimbursement for Part B drugs Support for increased transparency and accountability in Medicare's local determination process (S.794/H.R. 3635) 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices
- Issues related to reimbursement from the Department of Veterans Affairs.
- reimbursement for cancer care services
- Medicare, oncology, radiation and imaging reimbursement issues Medicare physician payments prompt pay discount Oncology payment disparities in Medicare and protecting access to community based cancer care Issues related to physician reimbursement for Part B drugs 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices S. 1895, the Lower Health Care Costs Act. H.R. 2296, the FAIR Drug Pricing Act of 2019. H.R. 3630, the No Surprises Act" The Lower Health Care Costs Act
- Medicare, oncology, radiation and imaging reimbursement issues Medicare physician payments prompt pay discount Oncology payment disparities in Medicare and protecting access to community based cancer care Issues related to physician reimbursement for Part B drugs 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices S. 1895, the Lower Health Care Costs Act. H.R. 2296, the FAIR Drug Pricing Act of 2019. H.R. 3630, the No Surprises Act" The Lower Health Care Costs Act COVID and the impact on cancer care
- Medicare, oncology, radiation and imaging reimbursement issues Medicare physician payments prompt pay discount Oncology payment disparities in Medicare and protecting access to community based cancer care Issues related to physician reimbursement for Part B drugs 340B, education related to need for sensible reforms in 340B that protect indigent beneficiaries and community oncology practices S. 1895, the Lower Health Care Costs Act. H.R. 2296, the FAIR Drug Pricing Act of 2019. H.R. 3630, the No Surprises Act" The Lower Health Care Costs Act COVID and the impact on cancer care drug pricing regulations
- Medicare, oncology, radiation and imaging reimbursement issues; medicare physician payments; Oncology payment disparities in Medicare.; Health information technology; application of the sequester to cancer drug reimbursement; prompt pay discount; safety and security of the prescription drug supply chain.
- H.R.2484, Seniors Access to Critical Medications Act of 2025
Related Investigations
Big Pharma's $452M Lobbying Machine
How pharmaceutical companies spend hundreds of millions to influence health policy.
Federal Lobbying Statistics 2025
The definitive stats — $15.2B total, industry breakdowns, and trends.
What Is Lobbying? A Complete Guide
How lobbying works, who does it, and why it matters.
Explore More
Data Sources: Senate LDA Filings
Last updated: February 2026
This site is an independent journalism project. Analysis and editorial content are not affiliated with or endorsed by any government agency.